Vertex Pharmaceuticals (VRTX): analysis and statistics
Return, volatility, Sharpe ratio and risk for Vertex Pharmaceuticals, a component of both the S&P 500 and the Nasdaq 100 in the Health Care. Data as of 2026-10-29.
| Last close price | $529.69 |
| Sector (GICS) | Health Care |
| Annualized return (3.0 yr) | +14.32% |
| Total return over period | +49.09% |
| Annualized volatility | 30.06% |
| Period volatility | 51.93% |
| Period T-bill | 12.40% |
| Sharpe ratio | 0.71 |
| Sortino ratio | 0.96 |
| Max drawdown | -29.07% |
| CVaR 95% (avg. loss, worst 5% of days) | -4.17% |
| Correlation with the S&P 500 | 0.25 |
| Period range | $343.00 – $557.96 |
| Trading days analyzed | 752 |
Over the last 3.0 years, Vertex Pharmaceuticals (VRTX) has posted an annualized return of +14.32% with annual volatility of 30.06%, a Sharpe ratio of 0.71. Its worst stretch (max drawdown from a peak) was -29.07%. Its correlation with the S&P 500 is 0.25, which means it moves fairly independently of the index, useful for diversification.
These are historical, realized metrics, not projections: they describe how the stock behaved, not how it will behave going forward. To see how VRTX would fit inside an optimized portfolio alongside other stocks, try the optimizer.
Optimize a portfolio with VRTX →
Other Health Care stocks
Is it part of the S&P 500?
Yes, Vertex Pharmaceuticals (VRTX) is of both the S&P 500 and the Nasdaq 100.
What is the Sharpe ratio? · How to optimize an investment portfolio